Treat to endoscopic remission in inflammatory bowel disease
Part of Digestive system clinical trials.
This study tests whether switching to a different treatment for inflammatory bowel disease (IBD) can achieve healing of the gut lining. It is for people whose symptoms are under control but who still have significant inflammation in their bowel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had Crohn's disease or ulcerative colitis for at least 6 months.
- You are currently taking IBD medications (like biologics or small molecules) and have been on the same dose for at least 3 months.
- You are in symptomatic remission (no bowel symptoms) without using steroids.
- You have recently had an endoscopy or imaging showing moderate to severe inflammation in your gut.
- You do not have an ostomy or ileal pouch (pouch created after colon removal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This trial tests an experimental drug (ISM5411) for people with active ulcerative colitis. The goal is to see if the drug can reduce inflammation and improve symptoms.
This trial tests a new treatment for people with ulcerative colitis (UC) whose disease is active despite taking only mesalamine or sulfasalazine. It aims to find a therapy that can reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.